Excelra Acquires BISC Global, Creating an International Bioinformatics Powerhouse With an Industry-Leading Platform and Service Offering.
19.4.2023 16:00:00 EEST | Business Wire | Press release
Excelra, a leading life science data and digital solutions provider, has acquired BISC Global, a bioinformatics and data analytics consulting company with offices across Europe and the USA. The acquisition creates an international powerhouse in consulting-led bioinformatics, with expertise in artificial intelligence, machine learning, and omics and next-generation sequencing data analysis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230419005464/en/
Excelra is a trusted partner to the world's top pharmaceutical and biotechnology companies, providing data, insight, and R&D technology services. Its interdisciplinary teams of biocurators, bioinformaticians, data scientists, and engineers deliver harmonized data, optimized analysis pipelines, and advanced applications to accelerate drug discovery and development.
BISC Global is a consulting-led platform and service provider specializing in bioinformatics, biostatistics, artificial intelligence, and machine learning. It provides data analysis, pipeline development, cloud computing, and data visualization services. It also offers next-generation platforms such as the Online Pipeline Platform (OP2), which supports streamlined analysis of bulk RNA-seq, single-cell RNA-seq, somatic variant calling, and germline variant calling data; and ImmunoRaptor, an analysis platform that makes it easy for researchers to manage and analyze immune repertoire sequencing data.
BISC Global's leadership believes the acquisition will expand bioinformatics innovation and benefit customers of both organizations. "We are excited about the acquisition by Excelra and are confident that the synergies between our two organizations will enable our consultants to provide best-in-class bioinformatics services to the life science industry," said BISC Global CEO Maarten Braspenning.
Excelra CEO Anandbir Singh Brar said, "The acquisition of BISC Global is a strategic move that enhances our capabilities and expands our reach in the bioinformatics field. The combined entity will be amongst the industry leaders in bioinformatics platforms and services, and will have a major positive impact on the future of bioinformatics and the life science industry."
The acquisition creates a game-changing bioinformatics powerhouse, committed to driving innovation at the intersection of science and technology.
About Excelra
Excelra provides data, insight, and R&D technology services to the world's top pharmaceutical and biotech companies. From offices in Boston, Utrecht, London, and Hyderabad, Excelra's 1000+ domain experts operate at the intersection of science and technology to empower life science innovation and accelerate drug discovery and development. Excelra provides integrated solutions from data to insight. It starts by structuring and harmonizing diverse scientific data sets. Then it builds custom R&D data engineering, cloud infrastructure solutions, tailored computational models, and optimized analysis pipelines to lead the way to groundbreaking discoveries. For more information, visit excelra.com.
About BISC Global
Founded in 2017, BISC Global has grown to be a Top 10 Bioinformatics Consulting and Services Firm, supporting the world's leading pharmaceutical and biotech companies. BISC provides data analytics, custom tool/pipeline development, and cloud solutions delivered on-site or remotely. It has a global workforce of expert consultants, operating from offices in Ghent, Belgium; Basel, Switzerland; Amsterdam, The Netherlands; Boston, MA; and San Francisco, CA. BISC supports analysis across multiple domains, including machine learning (data mining, pattern recognition, image analysis, (un)supervised learning, neural networks, deep learning, etc.), bioinformatics (single-cell transcriptomics, metabolomics, metagenomics, epigenomics, etc.), and statistics (experimental design, mathematic modeling, signal-to-noise enhancement, and independent data cross-validation). For more information, visit biscglobal.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005464/en/
Contact information
Jigesh Shah
Jigesh.shah@excelra.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Advanced MRI Imaging Reveals Changes in Muscle Composition and Fat Infiltration During Obesity Treatment1.10.2026 09:55:00 EEST | Press release
As obesity treatment continues to evolve, understanding what happens to muscle during weight loss is becoming increasingly important. At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD),AMRA Medical Chief Scientific Officer Dr. Jennifer Linge will present how advanced MRI-based analysis can provide a more detailed view of changes in muscle composition during obesity treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930545312/en/ Advanced MRI-based analysis can provide a more detailed view of changes in muscle composition during obesity treatment The presentation addresses an increasingly important question in obesity research: what happens to muscle as people lose weight?Understanding muscle composition changes is important because muscle health is about more than muscle size alone. Research using AMRA’s MRI-derived biomarkers has shown that muscle fat infiltration and muscle vo
Ares Strengthens Commitment to Plenitude Through €1 Billion Capital Contribution1.10.2026 09:30:00 EEST | Press release
Ares Management Corporation (NYSE: ARES), a leading global investment manager, announced today that Ares Alternative Credit funds (“Ares”) participated in a reorganization of the shareholding and governance structure of Plenitude through which Ares and Eni S.p.A (“Eni”) upsized their capital contribution by approximately €1.5 billion, of which over €1 billion is attributable to Ares, based on a pre-money equity valuation of Plenitude of €10.75 billion. Following completion of the transaction, Ares holds 26.24% of Plenitude’s share capital, with Eni holding 65.03% and Energy Infrastructure Partners (“EIP”) as an 8.73% shareholder. Ares first invested in Plenitude in 2025, acquiring a 20% stake in the business for approximately €2 billion. This transaction is geared towards strengthening Plenitude’s capital structure and introduces an enhanced governance framework that supports the company’s long-term growth ambitions. Ares and Eni will jointly control Plenitude, with Ares appointing thr
Orifarm Unveils 2031 Strategy to Accelerate Growth Across Europe, With Significant Expansion in Generics1.10.2026 09:10:00 EEST | Press release
With its five-year strategy, Fit to Scale, Orifarm sets out an ambitious path to scale across Europe, including a major expansion of its prescription medicines business from a Nordic footprint to a broader European platform. The strategy aims to double EBITDA to €300m and generate more than €3bn in revenue by 2031, marking the next step in Orifarm's journey as a diversified European pharmaceutical company bringing affordable medicines to more customers, patients and healthcare systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930257993/en/ Orifarm Headquarter, Odense Denmark “As European healthcare systems face rising demand, budget pressures, and supply challenges, Orifarm is uniquely positioned to improve access to affordable medicines and strengthen European supply. Our Fit to Scale strategy is about playing an even bigger role in meeting these needs and taking Orifarm to the next level,” says Mads Fink Eriksen,
Thales Launches Sentinel Envelope Plus to Protect Software Against AI-Assisted Reverse Engineering1.10.2026 09:01:00 EEST | Press release
Thales, a global leader in advanced technologies, today announced Sentinel Envelope Plus, a new addition to its Sentinel Envelope software protection solution that significantly hardens compiled applications against AI-assisted reverse engineering, automated zero-day vulnerability discovery, and automated exploit generation. Sentinel Envelope Plus applies multiple layers of protection to software applications, without requiring source code changes or any special compilation environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930063281/en/ AI-assisted tools are making it faster and easier to analyze software for vulnerabilities, reducing the specialist expertise and time traditionally required for reverse engineering. This creates new risks for software vendors, particularly when applications are deployed outside environments they control. On-premises, embedded and edge devices are at increased risk, as attackers
Thales Strengthens Data Security Posture Management to Address Emerging Risks of AI1.10.2026 09:00:00 EEST | Press release
Thales, a global leader in advanced technologies for cybersecurity markets, today announced CipherTrust Data Security Posture Management (DSPM). It is the first purpose-built DSPM offering designed to help organizations go beyond discovering exposed sensitive data and applying access-based remediation, enabling them to prioritize risks and protect their most sensitive data directly through encryption, masking, or tokenization natively within the platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930800339/en/ Sensitive data is increasingly distributed across cloud infrastructure, SaaS applications, on-premises systems, analytics environments and third parties. AI is accelerating the challenge as copilots, applications and agents gain access to enterprise data and information moves into new repositories and workflows much faster than traditional governance can keep pace. Security teams need to understand more than ju
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom